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Abstract
Currently available screening tests for prostate cancer (PCa) are neither very sensitive nor
specific. Microparticles (MP) are submicron tumor cell fragments released by PCa cells into
the circulation and offer a possible means of sampling the tumor. We evaluated the utility of
a MP blood test using nanoscale flow cytometry to distinguish patients with PCa from
patients with benign prostatic hyperplasia (BPH). We used monoclonal antibodies against
prostate specific membrane antigen, gastrin releasing peptide receptor and ghrelin peptide
ligand.
We found higher but statistically insignificant, PSMA and Ghrelin dual positive MP counts
in the BPH group. Our results show that although MP can be enumerated, better more
exclusive surface antigens and different antibodies are required to test the utility of MP for
this to be used as a "Next Generation Screening Tool" for PCa. In addition, comparison with
a more suitable control group would improve accuracy of the experimental test.
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Chapter 1

1

Introduction

1.1 General Overview
Prostate Cancer (PCa) is leading the list of all newly diagnosed visceral cancers in men,
and each year it is responsible for approximately 9.3% of all cancer related deaths (Jemal
et al. 2010). Currently, detection of PCa relies on a blood test known as Prostate Specific
Antigen (PSA), digital rectal examination (DRE), and transrectal ultrasound guided
biopsy (TRUS) of prostate. PCa is among the few solid organ malignancies which have a
surrogate tumor marker to detect the disease and monitor its course. Although PSA is a
highly sensitive and specific marker in the post treatment setting, especially post radical
prostatectomy, it has a very low sensitivity and specificity as a screening tool. In 2011,
the U.S. Preventive Services Task Force (USPSTF) drafted a recommendation against the
routine use of PSA screening at any age and in October 2012 the USPSTF website posted
that “Prostate cancer is a serious health problem that affects thousands of men and their
families. But before getting a PSA test, all men deserve to know what the science tells us
about PSA screening: there is a very small potential benefit and significant potential
harms. We encourage clinicians to consider this evidence and not screen their patients
with a PSA test unless the individual being screened understands what is known about
PSA screening and makes the personal decision that even a small possibility of benefit
outweighs the known risk of harms.” (USPSTF Co-Chair Michael LeFevre, M.D.,
M.S.P.H. May 22, 2012).

1

A large prospective study from Europe Organization for Research and Treatment of
Cancer (EORTC) looking at the role of PSA based screening program, ERSPC trial
(European Randomised Study of Screening for Prostate Cancer) in reduction of mortality
reported that a very large number of men need to be screened (1410 men) in order to save
one life (Schroder et al. 2009). The Prostate, Lung, Colorectal and Ovarian Cancer
(PLCO) Screening Trial, also investigating the usefulness of PSA as a screening tool,
showed that the incidence of death per 10,000 person-years was 2.0 (50 deaths) in the
PSA based screening group and 1.7 (44 deaths) in the control group (Andriole et al.
2009). Both of these studies demonstrated only a small benefit with PSA based screening,
thus underlining the point that PSA is not an ideal screening test. There is no absolute
cutoff level defined for PSA based screening, with the majority of clinicians using the
classic threshold of >4 mg/ml (Catalona et al. 1991). However, a large study looking at
2950 men with PSA of < 4mg/ml found that 15.2% of men with PSA’s in this range were
later found to have PCa (Thompson et al. 2004). Currently, based on “suspicious PSA”,
almost one million men in the USA undergo prostate biopsy each year and are exposed to
significant complications (Welsh et al. 2007). Prostate biopsy carries a risk of potential
complications such as hematuria and urinary tract infections and is reported to have a
6.9% hospitalization rate (Loeb et al. 2011). The current standard of performing a
prostate biopsy is for systematic sampling of the prostate using TRUS guidance.
Previously, only six cores (sextant) of prostate were obtained. However, this was found to
be inadequate and today, most centers perform a 10-12 core biopsy. This scheme of
biopsy has improved the detection rate to around 50% (Martinez et al. 2013). Therefore,

2

the majorities of men with suspicious PSA levels actually do not have PCa and are
unnecessarily exposed to the risks of biopsy.
To meet the challenge of developing a screening test superior to PSA, we propose a blood
test based on prostate cancer microparticles (PCMP). Microparticles (MP) are submicron
(< 1µm) particles released from cells during their growth, malignant transformation or
apoptosis (Rak, 2013). MP are released in the circulation and express surface receptors
inherited from their cells of origin (Andreu et al. 2014). We enumerated PCMP using a
combination of monoclonal antibodies (mAb) namely prostate specific membrane
antigen, gastrin releasing peptide receptor and ghrelin peptide ligand which have been
shown to bind to the extracellular portion of the receptors inherited by the MP derived
from the PCa cells. We used these PCMP counts to distinguish between plasmas from
patients with localized PCa and benign prostatic hyperplasia (BPH). The MP based test
has the potential of functioning as a “fluid biopsy” which can continually sample the
primary tumor to gain insight regarding the biology of these tissues.

1.2 Prostate Cancer
Prostate cancer (PCa) accounts for 27% of all newly diagnosed visceral malignancies
among men in the USA (Siegel et al. 2014). In 2014, it is estimated to affect 233,000
men in the USA and will account for 10% of all male cancer related deaths in men
(DeSantis et al. 2014). The Canadian Cancer Society estimates that 23,600 men will be
diagnosed with PCa in 2014, representing 24% of all new cancer cases in men and nearly
4,000 men will die from PCa in Canada.

This translates into 65 Canadian men being
3

diagnosed and approximately 11 men dying of PCa every day (www.cancer.ca). These
statistics place prostate cancer as one of the leading cancers affecting males in North
America. Prostate cancer typically has a long course, thus making it a major consumer of
the health care budget.

Overall, the lifetime risk of developing PCa is about 16.7%;

therefore one in six men will be diagnosed with prostate cancer in their life time. The
incidence of harboring a focus of clinically insignificant PCa is even higher as autopsy
studies performed on prostate glands obtained from men dying of all causes has shown
that 20% of men aged 50 to 60 years and 50% of men, aged 70 to 80 years, have
histologic evidence of carcinoma prostate (Carter et al. 1990). This disparity between
clinically significant cancer and incidental or indolent cancer has led to numerous efforts
to risk stratify this disease. None are perfect and study in this area is the major focus of
prostate cancer research. Naturally, this uncertainty provokes a genuine anxiety among
men at the risk of developing prostate cancer (Kotwal et al. 2012).
The definitive reason for development of PCa is not yet known. However, there are
several risk factors which increase the life-time risk of developing PCa. Risk factors
include family history, ethnicity, diet, and environmental factors (Crawford, 2003). The
risk of prostate cancer doubles among men having a first-degree relative with PCa and
rises up to eightfold or greater if both a first and second degree relative previously had
prostate cancer. Ethnicity is also a risk factor, as a wide variation in incidence has been
reported between different ethnic groups. Table 1 shows the incidence and mortality of
PCa among men in different ethnic populations (Campbell-Walsh Urology, tenth edition,
2010). Asian men have the lowest mortality rates and highest incidence and mortality
rates are observed in African–American men. Studies looking at the incidence of PCa
4

among immigrants, moving from an area of low incidence to higher incidence locations
have reported significant increase in incidence of PCa in the immigrants compared to the
natives in their country of origin. The increase in the incidence of PCa is more if
immigration happened earlier in life of an individual. The higher incidence is also seen in
the second generation of immigrants originating from areas of lower incidence.. This
signifies the influence of environmental factors in development of cancers (Shimizu et al.
1991).

5

Table 1. Incidence and mortality rate of prostate cancer in different ethnic groups
(Adopted from Wein AJ, Kavoussi LR, Novick AC, Partin AW & Peters CA, eds.
Campbell-Walsh Urology, 10th Edition. Philadelphia: Saunders, 2010.
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A high dietary intake of red meat, animal and polyunsaturated fats and milk appear to
increase the risk of prostate cancer whereas, fruit and vegetables and polyphenols may be
of preventive value for development of PCa. A review of dietary factors influencing the
risk of PCa does not suggest any conclusive evidence to elucidate the role of the above
agents in the development or prevention of PCa (Mandare et al. 2014). Anecdotal
experiences and small nonrandomized studies have long promoted Selenium, Lycopene
and Vitamin E as dietary supplements to prevent the development of PCa. To provide
conclusive answer to this query a large prospective, multicenter study was designed. This
Selenium, lycopene and Vitamin E Cancer Prevention Trial (SELECT) found no
preventive effects of any of these substances in the development of prostate cancer (Klein
et al. 2011). On the contrary, it provided some evidence that Vitamin E in high dose
actually increased the risk of development of PCa.
The prostate gland is a walnut-sized structure located at the bladder neck, and the urethra
passes through the center of this gland. Figure 1 illustrates the anatomic location and
relationship of prostate gland in a male pelvis (Campbell-Walsh Urology, tenth edition,
2010). The function of the prostate gland relates to its secretory role that nourishes and
protects sperm during insemination. As this gland is located just anterior to the rectum, it
can be easily palpated during digital rectal examination.
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Figure 1. Anatomical location of the prostate gland. The gland is shown in purple color
lying at the base of the urinary bladder and just anterior to the rectum. Adopted from
Wein AJ, Kavoussi LR, Novick AC, Partin AW & Peters CA, eds. Campbell-Walsh
Urology, 10th Edition. Philadelphia: Saunders, 2010.
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Figure 2. Zonal anatomy of prostate showing arrangement of zones of prostate. Adopted
from Wein AJ, Kavoussi LR, Novick AC, Partin AW & Peters CA, eds. CampbellWalsh Urology, 10th Edition. Philadelphia: Saunders, 2010.
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McNeal, in his original description of the zonal anatomy of prostate gland, described four
basic anatomic zones (McNeal, 1980). This description was further modified later and
Figure 2 shows the current understanding of the zonal anatomy of the prostate gland
(Campbell-Walsh Urology, tenth edition, 2010).
Prostate carcinoma typically arises from the peripheral zone and cancer cells originate
mainly from the secretory cells. Thus, prostate cancer is classified as ‘Acinar
adenocarcinoma’. Histologically, prostate carcinoma can range from well-differentiated
tumors which simulate normal prostatic glands, to poorly differentiated lesions which
have completely lost the glandular architecture and cannot be easily recognized as
descending from prostatic origin. A numeric grading system was introduced by Dr.
Donald Gleason to grade the degree of loss of differentiation (Gleason, 1974). PCa
exhibits a variety of histological patterns within a prostate cancer specimen. The Gleason
grading system incorporates this unique characteristic, in which the most predominant
pattern is called ‘Gleason Major’ and the second most common is called ‘Gleason
Minor’. Gleason score, a sum of Gleason Major and Minor is assigned to pathological
specimen incorporating both the patterns. This numeric score ranging from 2 to 10, out of
a maximum of 10, is meant to reflect the histological pattern accounting for biological
aggressiveness.

The

International

Society

of

Urological

Pathology

made

some

modifications to this system in 2005 and this system is still prevalent in grading of PCa
(Epstein et al. 2005). Table 2 illustrates the patterns with assignment of grades according
to the 2005 Modification of International Society of Urological Pathologist (CampbellWalsh Urology, tenth edition, 2010).
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Table 2. Modified Gleason’s histological grading system Adopted from Wein AJ,
Kavoussi LR, Novick AC, Partin AW & Peters CA, eds. Campbell-Walsh Urology, 10th
Edition. Philadelphia: Saunders, 2010.
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Prostatic carcinoma can metastasize through lymphatic or hematogenous dissemination.
Bone metastases are the most common site of hematogenous spread. Lymphatic
metastases occur frequently to the obturator lymph nodes (Campbell-Walsh Urology,
tenth edition, 2010).
Prostate cancer is staged according to the guidelines of the 7 th edition of American Joint
Committee on Cancer (AJCC). This staging system is commonly referred to as TNM
system. T stage refers to the volume of disease or the local extend of tumor, N reflects the
lymph node status and M categorize the metastasis, if present. Clinical TNM stage based
on local examination and imaging results is commonly referred to as cTNM. The
pathological TNM or pTNM, however, is the final stage assigned after histological
evaluation of the surgically removed prostate gland, along with regional lymph nodes.
Table 3 illustrates the details of TNM staging system (Campbell-Walsh Urology, tenth
edition, 2010).

12

Tx

Primary Tumor could not be assessed

T0

No evidence of Tumor

T1

Tumor not palpable

T2a

Tumor palpable in less than half of one lobe

T2b

Tumor palpable in more than half of one lobe

T2c

Tumor palpable in both lobes

Nx

Nodal metastasis cannot be assessed

N0

No nodal metastasis

N1

Nodal metastasis in single node less than 2 cm

N2

Nodal metastasis in single/multiple nodes less than 5 cm

N3

Nodal metastasis in multiple nodes more than 5 cm

Mx

Distant metastasis cannot be assessed

M0

No distant metastasis

M1a

Involvement of non regional lymph nodes

M1b

Involvement of bones

M1c

Involvement of other sites

Table 3. Tumor staging (TNM) according AJCC 7th edition
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In the last three decades there has been a migration in the stage at which PCa presents to
the health care provider (Scosyrev et al. 2012). Most of the patients now present with
asymptomatic and early stage cancer. Previously, a majority of patients were diagnosed
with symptomatic bony metastasis or urinary obstruction. In the nineties, a blood test
(PSA) was introduced in clinical practice that led to larger numbers of patients being
diagnosed at an earlier and potentially curable stage. Prostate biopsy is now mostly
recommended due to an abnormal PSA test. PSA is not a true tumor maker as such a
marker should only be raised in a malignant condition but PSA may be elevated in a
variety of other noncancerous prostate conditions. Interestingly, this PSA induced stage
migration has had a very little impact on reducing the overall mortality of PCa. This
observation led to the effort to critically appraise the role of PSA in reducing the
mortality of PCa. In 2011, the U.S. Preventive Services Task Force (USPSTF)
recommended against the routine use of PSA screening at any age. This recommendation
was based mainly on the results of two large prospective studies demonstrating that a
large number of men need to be screened (NNS) with PSA to detect PCa and prevent
cancer related death. The EORTC study showed that 1410 men need to be screened and
48 men needed to be treated (NNT) in order to prevent one death related to PCa
(Schroder et al. 2009). Although, the recent publication of extended follow-up (13 years)
of this cohort has shown improvement in the NNS (Schroder et al. 2014), PSA still does
not fulfill any currently acceptable standards for an ideal screening test. Urgent efforts are
required to develop a new screening test for detection of PCa.

14

1.3 Prostate Specific Antigen (PSA)
PSA is a glycoprotein enzyme from the kallikrein-related peptidase family and is
produced by prostatic epithelial cells. It is also known as gamma-seminoprotein or
kallikrein-3 (KLK3). The physiological role is in the liquefaction of semen. It helps in
dissolving the coagulum and allows the sperm to swim freely for insemination.
Prostate specific antigen was first purified in humans in 1979 (Wang et al. 1979). Prior to
this, prostate acid phosphatase (PAP) was used as a marker for PCa. PAP was nonspecific for prostate cancer and was elevated in a variety of other conditions like Paget’s
disease. Prior to the establishment of PSA as a blood-based tumor marker, it was shown
to be an exclusive immunohistologic marker for prostatic cancer. In an experiment using
histological sections, it was observed that all sections from primary and metastatic
prostatic cancer reacted positively with PSA, whereas non-prostatic neoplasms did not
stain with PSA (Nadji et al. 1981). Later, PSA was established as a blood test for
monitoring the response of treatment for PCa (Stamey et al. 1987). Soon thereafter, PSA
was also introduced as a screening tool for early detection of PCa (Catalona et al.1991).
Using a cutoff of 4mg/ml, it was shown that this test was able to detect asymptomatic
PCA in 22 % cases. Other studies looking at the performance of PSA as a screening tool
have shown variable results and depend on the PSA cutoff used for screening. For
example, increasing the cutoff of PSA to higher levels improves the predictive value.
However, if a higher cutoff is used then the number of cancers detected at early stage
decrease and more cancers are diagnosed at an advanced stage. The lack of specificity at
lower cutoffs subject many patients with elevated PSA, often secondary to noncancerous
causes, to a prostate biopsy. This underscores the fact that PSA is able to identify patients
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with prostate disease and is not specific for PCa. The area under the curve (AUC) of the
receiver operating characteristic (ROC) curve is between 0.56 and 0.70 for the ability of
PSA to identify patients with cancer, where a score of 1.0 is perfect discrimination and
0.5 is a coin toss (Brawer et al. 1999). Common non-cancerous causes of elevated PSA
levels are prostatic infection, trauma, and BPH. Studies have also shown that using the
classic cutoff of 4mg/ml will result in missing significant number of prostate cancer cases
(Schroder et al. 2008). If the cutoff of < 4mg/ml is considered as a negative test, a large
study found 15.2% men in this group were actually later diagnosed to have prostate
cancer, and according to AUA risk classification, 14.9% of these patients exhibited high
risk disease (Thompson et al. 2004).
To improve the predictive value of the PSA test, a number of dynamics of PSA have been
tested. PSA density (PSAD) is one such tool. The calculations for PSAD are based on the
concept that the normal prostate gland produces PSA but at lower concentrations. Each
gram of normal prostate gland contributes to the total PSA but if there is a focus of
cancer in the gland it produces significantly higher PSA. The total weight of the prostate
is calculated by transrectal ultrasound and a predicted PSA is calculated by multiplying it
by 0.12. Any value above the predicted value is suggestive of PCa. In one study, no
cases of BPH were found in men with PSAD of > 0.1 mg per each gram of prostate
(Benson et al. 1992). However, 2 out of 41 patients with prostate cancer had a PSAD of
0.05mg/gm or less. PSAD is a great tool to rule out BPH in men with high PSAD but
fails to reliably rule out PCa, when PSAD is low. Recently, the role of PSAD is also
being highlighted in the follow up of patients with low risk PCa managed with active
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surveillance. A higher PSAD is found to be positively associated with the risk of
progression and need for active treatment (Welty et al. 2014).
Age related PSA is another method to improve diagnostic efficiency. These age-specific
reference ranges are designed to enhance the predictive value of PSA as a more
discriminating tumor marker for detecting clinically significant cancers in older men
(increasing specificity) and to find more potentially curable cancers in younger men
(increasing sensitivity) (Oesterling et al. 1993).
PSA in circulation exists in both free form and complex form, bound with alpha 1antichymotrypsin (ACT). Complex PSA is raised in PCa (Leinonen et al. 1993). A free to
total PSA ratio of < 15 to 20% is generally considered to increase the risk of cancer
(Oesterling et al. 1995). However, there is no exact watershed level. PSA velocity, the
rate at which the PSA rises, is also used to improve the predictive value, where if the
PSA increases by >0.75mg/ml per year it is considered to be an indication for prostate
biopsy (Carter et al. 1993).
Extensive research in finding ways to promote the utility of PSA as a screening tool has
failed to develop a perfect model capable of confidently selecting men suitable for
aggressive and life-saving treatment.

1.4 Trans-rectal ultrasound (TRUS) guided Biopsy
This is the main modality of obtaining prostate tissue for histological diagnosis.
Transrectal ultrasound is used as a guide to obtain systematic samples from the prostate.
A probe is introduced into the rectum and a needle biopsy gun is used to obtain core
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biopsies. Specific templates are used to systematically sample the prostate gland.
Additional samples may be obtained from sonographic or clinically suspicious areas.
The chances of finding a focus of prostate cancer on TRUS biopsy increases with the
number of cores taken but this may also increase the risk for complications which include
hematuria, rectal bleeding and urinary tract infection. In North America, more than 1
million prostate biopsy procedures are performed each year, with approximately 25%
being positive for cancer and approximately 75% negative for cancer (Thompson et al.
2004). The risk of complications after a prostate biopsy is not trivial, as hematuria occurs
in 66% patients and rectal bleeding in 9% patients. Urinary tract infections occur in 0.5 to
3% patients and in rare cases these can lead to mortality. SEER- Medicare data reveals
that the 30-day hospitalization rate after TRUS biopsy was 6.9%, which was significantly
greater than the 2.7% risk of hospitalization in the control population (Loeb et al. 2011).
Even after adjusting for age, ethnicity and comorbidities, prostate biopsy is associated
with a 2.65-fold (95% CI 2.47-2.84) increased risk of hospitalization within 30 days, p
<0.0001 (Loeb et al. 2011). Interestingly, the risk of infectious complications requiring
hospitalization after biopsy was significantly greater in more recent years, probably a
reflection of a trend to acquire more biopsy cores. Increasing the number of cores of the
biopsy increases the sensitivity but also increases the risk of complications. It is now
recommended to have at least 10 cores for prostates <50 gms and up to 18 cores for
larger glands (Chun et al. 2010). But even increasing the number of cores to >20, does do
not eliminate the possibility of missing a focus of carcinoma and this may often require a
repeat biopsy. If we develop a better marker of the diagnosis of PCa, we may be able to
prevent a large majority of men undergoing a prostate biopsy. This test is critically
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needed for screening PCa. In theory, every additional 5% increase in accuracy rates for
such a prostate screening test would eliminate approximately 165,000 unnecessary
biopsies and 6,930 hospitalizations each year in North America. This would potentially
result in significant health care savings and improve the quality of life of our patients.
To meet the challenge of a screening test superior to PSA, we propose a prostate
microparticle-based “fluid biopsy” which continually samples the prostate and its primary
tumor. The microparticles may contain biological information from the parent cells and
may help to gain insight regarding the biology of these tissues without the need of
obtaining a tissue sample.

1.5 Microparticles
Microparticles (MP) are defined as plasma membrane derived structures of a diameter of
less than 1000nm. They are released from the cell upon activation, death, apoptosis or
malignant transformation (Rak, 2013).

The release of microvesicles was first described

in 1967 by Wolf while studying the particulate dust formed by active platelets (Wolf,
1967). MP are released directly from the cell membranes whereas, exosomes are
enveloped by a inverted cell membrane that was first internalized and then released. Cell
cultures from various normal and neoplastic cell lines have shown that exfoliated vesicles
are present in the cell culture medium (Trams et al. 1981). These microparticles were
found

to

contain significantly higher amounts of sphingomyelin (SM) and total

polyunsaturated fatty acids. This study concluded that the shed MP constitute a select
portion of the plasma membrane. Examination by electron microscopy showed the
vesicles had an average diameter of 500 to 1000 nm. These particles were previously
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labeled as “cell dust” or “cell garbage”, but advancements in imaging technology has
enabled us to understand them better and this has opened up new avenues of research
(Leong et al. 2011).
Living cells, through outward blebbing of the plasma membrane, generate MP from the
region of membrane lipid rafts. They exhibit high levels of exposed phosphatidylserine
(PS), integrins and metalloproteinases (Rak, 2013).
The process of the generation of a MP starts with vesiculation, initiated by focal and
short-lived

alterations in the plasma membrane phospholipids brought about by

enzymatic changes. These changes produce a focal asymmetry, which is seen as a
tentacle or a bleb. Some of these tentacles are shed off and enter the circulation. This is
an energy-dependent and active mechanism, which maintains an architectural uniformity
of the cell. This process guarantees that phosphatidylcholine and SM remain on the outer
surface of the plasma membrane and phosphatidylserine, and phosphatidylethanolamine
are present on the inner side. This action is brought about by lipid-translocating enzymes
(flippases). Calcium is an integral part of this process because cytosolic calcium initiates
significant changes in the state of the enzymes responsible for generation of MP.
Aminophospholipid translocase, scramblase, gelsolin, lipid, floppase, and calpain are the
main enzymes identified to play an important role in this process (Rak, 2013). This
ultimately results in externalization of PS and changes in the membrane geometry. These
cytoskeletal interactions are critical for the formation of the tentacles or blebs, which
ultimately leads to the formation and release of a MP.
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MP can be visualized using electron microscopy for morphological characterization.
Gold-labeled immune electron microscopy was first used to assess the urinary MP
(Mitchell et al. 2009).

With the microparticles fluorescently labeled, MP can also be

visualized indirectly using confocal microscopy (CM). However, MP are too small for
direct visualization with standard CM. The lipophilic fluorescent dyes conjugated with
antibodies against the antigens expressed on the plasma membranes of the MP can help
detect them with relative ease. Dr. Leong, at our laboratory has validated the presence of
MP analyzed using flow cytometry (Leong et al. 2011) and by atomic force microscopy
(Leong et al. 2010). Figure 3 shows atomic force microscopy images of prostate cancer
microparticles.
The exact role of these MP is still elusive but there is great enthusiasm in the scientific
community to explore the role of these structures in the vesicular transportation system
both for intracellular and extracellular communication. In 2013, James Rothman, Randy
Schekman and Thomas Sudhof were presented with the Nobel Prize for their work on the
role of micro vesicles for intracellular transportation. Similarly, plasma membrane
derived

microparticles

may

also

have

a

role

in

the

extracellular

transportation/communication (Camussi et al. 2010).
As with other newly discovered structures, these < 1 µm structures have been described
in

the

literature

exosomes,

using

oncosomes,

a

variety

of terminologies;

secretory vesicles,

microparticles,

microvesicles,

ectosomes are a few examples. The

terminologies have mostly originated from either the disciplines in where they have been
studied or more recently based on the size. The most widely studied structures in this
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category are the Exosomes that have a size up to 500nm (Pan, 1983) and have an
established role in cellular communication.

.

Figure 3 Atomic force microscopy images depicting the structure of individual prostate
specific membrane antigen (PSMA) positive microparticles
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However, the mechanism of release of exosomes is very different as they are first
internalized and then reprocessed for release (Duijvesz et al. 2011). Ectosomes are
plasma cell derived structures but are mainly released as a result of apoptosis (Diamant et
al. 2004).

To avoid use of confusing terminologies we will refer to microvesicles,

exosomes, oncosomes, secretory vesicles and ectosomes as ‘Microparticle (MP)’ in our
discussion. There is growing consensus that MP is the best-suited terminology to describe
these biologically diverse structures.
The exact physiological importance of these structures in the development of cancer is
not known. MP are enriched with specific antigens (Clayton et al. 2009). Elegant
experiments in immunology have shown that MP affects the immune system by
expressing and processing antigens (Raposo et al. 1996). As MP retains the surface
characteristics of parent cells they may have a role in antigen presentation and
immunomodulation. They may play a role in either promotion or prevention of
metastasis. Assuming this is the mechanism of their release into the circulation, this
feature may be exploited to develop diagnostic markers, which can function as a “fluid
biopsy” of the entire gland.
Currently, prostate cancer microparticles is an emerging topic in oncology research, but
many researchers lack the instrumentation needed to translate this work into clinical
applications. Enumeration of MP in a sample remains a challenge. The number of MP is
generally estimated by measuring the amount of protein (Nilsson et al. 2009).
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Fluorescence-activated cell sorting (FACS) technology i.e. flow cytometer is capable of
enumerating MP but identification of organ specific MP, which are relatively tiny
compared to a cell, is difficult using a regular flow cytometry system due to the
limitations of laser detectors. Other visualization techniques such as electron microscopy
(EM) and confocal microscopy (CM) described previously are good for morphological
characterization but cannot perform quantitative assays in a high throughput manner. A
combination of enzyme-linked immunosorbent assay (ELISA) for exosome quantification
has been used (Logozzi et al. 2009). In this experiment they used two different
transmembrane proteins that are present on all exosomes. They postulated that by using
one general transmembrane protein or so called ‘capture protein’, it is possible to identify
exosomes and by using ‘tissue- or cancer-specific’ transmembrane protein, the number of
exosomes derived from a specific tissue can be measured.
We used a similar hypothesis and selected prostate specific membrane antigen (PSMA)
as the capture marker for identification of prostate specific MP. For cancer specific
marker we selected ghrelin peptide and gastrin releasing peptide receptor (GRPR). We
postulated that a combination of more than two markers would improve our ability to
select the population of prostate cancer MPs. We proposed to do this using flow
cytometry. Improvement in this technology with development of Agogee, A-50 nanoscale
flow cytometer (® Apogee Flow systems, Hertfordshire, UK) has provided us the
capacity to enumerate particles of less than one micron.
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1.6 Instruments
We used a specialized instrument that analyzes cell fragments in a high-throughput,
multi-parametric manner. This nanoscale flow cytometer is manufactured by Apogee
Flow systems Incorporation, Hertfordshire, UK. The “Apogee A-50 micro nanoscale
flow cytometer” shown in Figure 4, is specifically designed to analyze and enumerate
cancer microparticles. This machine has three lasers installed; the Laser wavelengths are
375nm, 405nm, 488nm and 635nm. The multiple light scattering and fluorescence
detectors help increase the detection limit to <100nm and increase the resolution to
<10nm. Figure 5 shows the basic design of the machine, the florescence channels and the
laser with exposure to the column of cells. This machine is equipped with Peripheral
Component Interconnect Express (PCIe), high-speed computer software used for data
acquisition. It employs the latest Altera™ technology for data acquisition at speed of up
to 100k events per second.

Conventional flow cytometers rely on fluorescent probes to

measure biological particles smaller than 500nm, this may produce dim signals and data
may be inconsistent. The A50-Micro's light scatter performance allows small particles to
be better discriminated.
Since our previous study demonstrated that prostate cancer MP are abundant in plasmas,
we performed

multi-parametric analyses with prostate-specific and cancer-specific

biomarkers (Siddiqui et al. 2014). We used a combination of antibodies that bind
prostate-specific and cancer-specific markers present in just 20 µl of patient plasma. Our
initial experience of enumeration of MPs in the plasma samples from a PCa patient
before and after radical prostatectomy and our previous pilot study encouraged us to use
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this machine to develop a test to distinguish patients with benign prostatic hyperplasia
(BPH) from patients with prostate cancer.
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Figure 4. Apogee A50 Nanoscale Flow cytometer
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Figure 5. Fundamental framework of a flow cytometer with florescence channels and the
laser detectors
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1.7 Prostate Cancer Surface Receptors
Cells originating from a specific organ typically manifest some receptors exclusive to that
organ. This usually helps in classifying the cell to the organ of origin. Histological
interpretation of specimens from metastatic sites with unknown primary lesion have long
relied on using monoclonal antibodies against cell specific receptors to identifying the
origin of these metastatic lesions. Recently, they have attracted attention and are
increasingly used to develop therapeutic and diagnostic agents for treatment of cancers
(Deckert et al. 2009). These antibodies are conjugated with florescence dyes and used in
imaging modalities. For example, the Prostascint scan uses PSMA to look for metastatic
lesions from PCa (Rosenthal et al. 2001). Ghrelin has been used as a PET imaging agent
to identify foci of carcinomas in the prostate gland (Fowkes, 2014). We hypothesize that
these antibodies may be used to identify microparticles, as it is postulated that a MP
retains the surface receptors from the parent cells. With the use of appropriate antibodies
it may be possible to establish the lineage of the MP. Monoclonal antibodies (mAbs) are
highly specific and adaptable for targeting cells. We used two antibodies against two
surface receptors expressed on PCa cells namely, prostate specific membrane antigen
(PMSA) and gastrin releasing peptide receptor (GRPR). We also used a peptide-ligand
called Ghrelin. The antibodies and the peptide-ligand were conjugated with fluorescent
agents and used to enumerate the MP using flow cytometry.

1.7.1 Prostate specific Membrane Antigen (PSMA)
PSMA is a type II transmembrane protein. It has a helical structure with an N-terminal
cytoplasmic tail and was first cloned in 1993 (Israeli et al. 1993). This transmembrane
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protein consists of a small intracellular domain of 19 amino acids, a transmembrane
domain of 24 amino acids, and a large extracellular domain of 707 amino acids. The
extracellular portion consists of a binding motif, including two zinc ions. The presence of
PSMA is not actually unique to the prostate (Sacha et al. 2007). Its structure is almost
identical to folate hydrolase and it is confirmed to be present in four sites in the body:
prostate (secretory acinar epithelium), kidney (proximal tubules), nervous system glia
(astrocytes and schwann cells), and the small bowel (Mhawech et al 2007). The
physiological significance of PSMA in not completely understood in the prostate gland
but it may be linked to the presence of folates in the seminal fluid. As intracellular folate
is more abundant in rapidly dividing cells it is postulated that it may be more expressed in
the higher grade prostate cancers.
PSMA was first identified in the prostate using IgG1 monoclonal antibody called 7E11C5.3. This antibody was developed using the prostate cancer cell line known as LNCaP
and was also used in development of Prostascint scan (Horoszewicz et al. 1987). This
scan was approved by U.S. Food and Drug Administration (FDA) to be used as
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In-

labeled form (ProstaScint, Cytogen, Philadelphia, PA) but gained limited success
(Rosenthal et al 2001). The main flaw in this antibody was that it had affinity for the
intracellular portion and hence was not useful to identify living cells. Wolf et al
developed three other mAbs (3/A12, 3/E7, 3/F11), which show a strong and specific
extracellular binding to PSMA (Wolf et al. 2010). Wolf also demonstrated that 3/E7 was
compatible with flow cytometric analysis and showed high affinity to human prostate
tissue. This antibody could be obtained with >95% purity from the hybridoma.
Progressively increasing expression of PSMA has been demonstrated in BPH, high grade
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prostatic intraepithelial neoplasia (PIN) and prostate cancer (Bostwick et al. 1998).
Similar association of PSMA expression in high grade prostate cancer has been shown by
other investigators (Wright et al. 1995). This data support potential clinical use of PSMA
in the diagnosis of PCa.

1.7.2 Ghrelin
Ghrelin peptide is a ligand for Growth Hormone Secretagogue Receptor (GHSR). Growth
hormone (GH) is mainly released from the pituitary gland in response to growth hormone
releasing hormone (GHRH) but there is also another pathway related to G-protein
coupled receptor called growth hormone secretagogue receptor (GHSR). This receptor
was first cloned in 1996 and unlocked the door for future research in this direction
(Howard et al. 1996). The ligand for GHSR was purified in 1999 and named as Ghrelin,
‘ghre’ is the Proto-Indo-European root of the word 'grow' (Kojima et al. 1999). Ghrelin
is composed of 28 amino acids, in which the 3-serine residues are n-octanoylated. The
acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation
at 3-serine is essential for the activity. GHSR is also differentially expressed in human
breast cancer cell lines (Casoni et al. 2001). Other studies have also documented that
differential expression of GHSR in PCa and showed that Ghrelin has a role in growth of
prostate cancer cell lines (Jeffery at al. 2002). He observed a 33% increased growth in
the PC-3 cell lines when stimulated by ghrelin. Our collaborator, Dr. Luyt and colleagues
at Western University modified the structure of ghrelin and created a novel fluorescent
ghrelin analogue. They demonstrated the binding and uptake of this fluorescent ghrelin
analogue in human PCa cells and showed the ability of Ghrelin to specifically bind PCa
over normal adjacent tissue (Rosita et al. 2009). In our previous work using ex vivo
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tissue, we were able to demonstrate that this novel fluorescein-ghrelin probe was able to
distinguish between benign and cancerous cell lines and therefore has potential to be
explored as a marker for diagnosis of PCa (Lu et al. 2012). In our pilot study, we have
shown the usefulness of Ghrelin as our cancer-specific biomarker to define the population
of prostate cancer microparticles in plasma. In the pilot study, we enumerated PSMA+
and GHSR+ microparticles in plasmas from three patient cohorts and found higher counts
of PSMA+ GHSR+ dual positive MP in the metastatic and localized prostate cancer
patient cohorts compared to the low counts observed in healthy volunteers. Based on this
experience we elected to investigate Ghrelin as a biomarker in this study.

1.7.3 Gastrin Releasing Peptide Receptor (GRPR)
GRPR is a G-protein coupled receptor belonging to the family of Bombesin receptors.
Bombesin is a 14-amino acid peptide, originally isolated from the skin of the European
fire-bellied toad (Bombina bombina) (Nakajima et al. 1980). Erspamer, further
characterized and isolated them (Erspamer, 1988).

Gastrin Releasing Peptide (GRP)

mediates its action through the membrane-bound GRPR. It activates several signaling
pathways including those involved in cell cycle regulation (Jensen et al. 2008). GRPR
expression has been identified on PC-3 prostate cancer cells (Bologna et al. 1989). Their
differential expression was also documented in the breast cancer cell line (Giacchetti et
al. 1990). These studies lead the way for further exploration of GRPR in the process of
carcinogenesis. It has also been shown that antagonists of GRP can inhibit the growth of
prostate cancer cells. (Milovanovic et al. 1992). GRPR also has been shown to be over
expressed in PCa (Ananias et al. 2009). In this study they found GRPR staining in lymph
node metastases in 85.7% of cases and PSMA staining in 100%. GRPR expression was
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found to be present in 52% of the bone metastases. Another study also looked at GRPR
expression in 299 primary prostate carcinomas and found 77% cases positive for GRPR
(Beer et al. 2012). They also found inverse relation with the grade and volume of disease.
In this study our hypothesis is that PCa cell release MP in the circulation. These MP
express surface receptors which are inherited from their cell of origin. Our literature
review suggests that PSMA, GRPR and GHSR are abundantly expressed on PCa cells..
Monoclonal antibodies and ligands specific for these receptors can be used as biomarkers
for PCa. A combination of these biomarkers including PSMA mAb and Ghrelin-peptide
and/or GRPR mAb can help us isolate PCMP in plasma samples to discriminate patients
with PCa from patients with BPH.
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Chapter 2

2

Pilot Study: Enumeration of Prostate Cancer Microparticles
as a Tool to Identify Prostate Cancer

2.1 Introduction
The search for development of an ideal tumor marker for prostate cancer has been on
going for the better part of the last half century. There is a long list of emerging
biomarkers for diagnosis and prognosis of prostate cancer (PCa) (Velonas et al. 2013).
Only a few biomarkers have been able to survive the stringent tests of large clinical trials
and prostate specific antigen (PSA) continues to be the most widely used marker for PCa.
The current guidelines by the American Urology Association (AUA) only permit PSA
testing for individuals between age 55 and 64 who understand the risks associated with
PSA based screening (www.auanet.org).

The AUC analysis for ability of PSA to

confidently diagnose PCa is in the range of 0.56- 0.70 (Brawer et al. 1999). A recent
report of the ESRPC trial report that 781 men are needed to be screened with PSA to
prevent one PCa related death (Shroder et al. 2014). To meet the challenge of developing
a screening test superior to PSA, we proposed a microparticle (MP) based test that
enumerated prostate cancer MPs in minute volumes of patient blood in a high-throughput
and multi-parametric manner. This pilot study is aimed to validate the clinical utility of
this test to successfully distinguish patients with PCa from those who did not have
cancer.
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2.2 Material and Methods
We used A-50 Apogee, nanoscale flow cytometer which is specifically designed to
analyze and enumerate cancer microparticles, to study prostate cancer microparticles
present in four cohorts of patients:
a. Healthy volunteers (HV) (n=24); Included young men and women aged <35 with
no known cancers.
b. Benign Prostatic Hypertrophy (BPH) (n=10); Included men who had a normal
digital rectal examination and had a transurethral resection of prostate with a
pathologic diagnosis of BPH.
c. Localized Prostate Cancer (n=112): Samples obtained from Ontario Institute of
Cancer (OICR) from patients undergoing radical prostatectomy for localized
prostate cancer.
d. Metastatic Prostate Cancer (n=23): Included samples from patients with
metastatic castrate resistant prostate cancer.
We used a monoclonal antibody specific to the extracellular portion of PSMA (PSMARPE mAb) and ghrelin peptide, a growth hormone secretagogue receptor (GHSR) ligand
(Ghrelin-FITC ligand) to identify and enumerate dual positive prostate cancer
microparticles (PSMA + Ghrelin dual positive).
For the HV and BPH group we collected 1 vacutainer from each patient (10 mL sodiumheparin Green top tubes) of whole blood. The vacutainer was centrifuged at 2000 RCF
for 20 min. This resulted in the blood separating into two distinct layers, a red layer
(erythrocytes) and a yellow upper layer (platelet poor plasma-PPP). Using a plastic
disposable pasteur pipet, the PPP was transferred into 3ml tubes and stored at -80ºC.
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Before the experiment, we thawed PPP in the tube and transferred 20 uL to a sterile 1.5
mL eppendorf tube. This was designated as tube A. Using a 20 uL pipetman, another 20
uL of PPP was transferred to another sterile 1.5 mL eppendorf tube and labeled as tube B.
2uL each of IgG-FITC antibody and IgG-RPE antibody was then added to tube A. 2uL of
Ghrelin-FITC ligand and 2uL of PSMA-RPE antibody was also added to tube B. Both the
tubes A and B were mixed and immediately incubate in the dark for 30 min. 600uL of
sheath fluid (1X PBS, pH 7.4) was then added to each tube and samples were vortexed.
Samples were then analyzed using flow cytometry. Samples were analyzed in triplicates
and the average calculated.

2.3 Results
We analyzed 169 plasmas and found significantly higher counts (p<0.01, ANOVA, bon
ferroni test) of PSMA + Ghrelin, dual positive prostate cancer microparticle (PCMP) in
patients with prostate cancer as compared to BPH and healthy volunteers. The numbers
of PCMP in each group are shown in Figure 6.
However we did not find any significant correlation between the number of PCMP and
Gleason score (one-way ANOVA test). The number of PCMP in each category of
Gleason score are shown in Figure 7.
We did not find any correlation between number of PCMP and Tumor Stage (one-way
ANOVA test). Figure 8 shows the number of PCMP in each ‘T’ category. Similarly no
statistical difference was observed between the numbers of PCMP in the localized group
and metastatic group. Figure 9 shows the distribution of PCMP counts in various patient
cohorts. The scatter plots with means and respective 95% confidence intervals (red lines)
reveal a cutoff (green dashed line) for distinguishing BPH patients from patients with
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Figure 6. Comparison of Number of Prostate Cancer Microparticles (PCMP)
Expressing PSMA+ Ghrelin, Dual Positive Events in Plasmas from Four
Groups, Including Healthy Volunteers (HV) and Benign Prostatic Hypertrophy
(BPH), Representing A Population with No Cancer and Other Two Groups;
Localized Prostate Cancer and Metastatic Prostate Cancer, Representing A
Population with Cancer..
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Figure 7. Comparison of Number of Prostate Cancer Microparticles (PCMP) Expressing
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Prostate Cancer Patients with
Gleason Score 3+3, 3+4, 4+3, 4+4 and 5+4.
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Figure 8. Comparison of Number of Prostate Cancer Microparticles (PCMP) Expressing
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Prostate Cancer Patients with
Tumor Stages; T2a, T2b, T2c and T3.
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Figure 9. Distribution of Number of Prostate Cancer Microparticles (PCMP) Expressing
PSMA+ Ghrelin, Dual Positive Events in Plasmas from Four Groups, Including Healthy
Volunteers (HV) and Benign Prostatic Hypertrophy (BPH), Representing A Population
with No Cancer and Other Two Groups; Localized Prostate Cancer and Metastatic
Prostate Cancer, Representing A Population with Cancer.. The Green Dashed Line
Distinguishes Patients with PCa from patients with No Cancer.
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PCa. With this cutoff, the blood test is 89% accurate in identifying patients with PCa
(localized PCa cohort) with 20% of patients being mistakenly identified as having PCa.

2.4 Discussion
Prostate cancer (PCa) is a leading cause of cancer-related death of men in the western
world (Siegel et al. 2014). Majority of men are diagnosed with PCa based on a raised
prostate specific antigen (PSA). Since its introduction, PSA has generated intense debate
as an effective

screening tool for PCa (Catalona et al.

1991).

The recent

recommendations by United States Preventive Task Force (USPSTF) has concluded that
PSA based screening produces unacceptably high rates of false positive results and
causes more harm than benefit.
The National Cancer Institute defines a biomarker as “a biological molecule found in the
blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a
condition or disease”. An ideal biomarker for PCa should not only be able to screen with
high sensitivity and specificity but also predict the course of disease and help select high
risk individuals for aggressive treatment. The ideal tumor marker should be economical,
reproducible, non-invasive, not time consuming to perform and easily accessible for
majority of population (Velonas et al. 2013).
Microparticles (MP) are plasma membrane derived structures of a diameter of less than
1000nm. The introduction of MP as a diagnostic test could enable more sensitive
detection than current methods due to their origin and specificity (Rak 2013). A recent
review of MPs, highlighted the importance of these sub micron structures as a biomaker
for cancer (Gyorgy B et al. 2011). MP are secreted into the circulation, urine and semen,
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thus if reliably identified, they can be exploited as biomarker treasure chests for prostate
cancer (Dujivesz D et al. 2011). The main function of MP is proposed to be cell-to-cell
communication but they are likely to play a significant role in oncogenesis (Yang et al.
2011). Exosomes (very similar to MP) have also been shown to promote metastasis by
avoiding detection by immune system (Yang et al. 2007).
We developed a MP based blood test to identify patients with PCa using a combination of
monoclonal antibody for prostate specific membrane antigen (PSMA) and ghrelin
peptide, a ligand for growth hormone scretagogue receptor (GHSR). PSMA has been
shown to be highly expressed on prostate cells and differential expression has been
documented on high grade prostate cancer compared to BPH and normal prostate gland
(Wright et al. 1995). Similarly, ghrelin has been shown to bind more strongly with PCa in
both in vitro and ex vivo experiments (Lu et al. 2012).
Our results showed that PSMA + Ghrelin, dual positive MP are more abundant in PCa
patient plasmas compared to plasma samples from healthy volunteers and patients with
BPH. Compared with other established makers like PSA and prostate cancer antigen
(PCA) 3 score, which have a diagnostic accuracy of 56% to 72% (Crawford et al. 2012).
This blood test is able to identify PCa with a diagnostic accuracy of 89% in only a minute
volumes of patient blood in a high-throughput and multi-parametric manner.

2.5

Conclusion

Our initial results show that the MP based blood test using PSMA+ Ghrelin as biomarker
for PCa is capable of fulfilling the requirements of an ideal tumor marker and has
potential to be the "Next Generation Screening Tool" for Prostate Cancer.
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2.6

Limitations

The major limitation of this study was the disproportionately higher number of patients
with prostate cancer. The total numbers of patients with PCa were 135 (112+23)
compared to only 10 patients with BPH. Even if we combined BPH and healthy
volunteers, the number was only 34 (24+10). In this pilot study the sample were neither
randomized nor was the observer blinded.
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Chapter 3

3

Prostate Cancer Microparticles as a Next Generation
Screening Tool for Prostate Cancer

3.1 Introduction
Prostate cancer (PCa) is the leading cancer among adult males and is one of the few solid
organ malignancies, which can be diagnosed and monitored using a tumor marker i.e.
prostate specific antigen (PSA). However PSA is not a true tumor marker and is also
produced by normal prostate gland and may be raised in a number of benign conditions.
Large studies have shown that >50% of men with raised PSA do not have PCa and are
unnecessarily subjected to transrectal ultrasound (TRUS) guided systematic biopsy of
prostate gland (Martinez et al. 2013). In 2012, the U.S. Preventive Services Task Force
(USPSTF) recommended against the routine use of PSA screening at any age. Clearly,
PSA does not fulfill any currently acceptable standard of a screening test and a new
screening test is needed. To meet this challenge, we propose a prostate cancer
microparticle based test.
Microparticles (MPs) are fragments of cells that are released by the prostate gland as the
cells undergo division, necrosis, apoptosis, and/or exocytosis (Rak, 2013). Using a
monoclonal antibody specific to the receptors expressed on prostate cancer we can
identify prostate cancer microparticles (PCMP) and these novel markers may be used for
diagnosis and monitoring of PCa.
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3.2

Objective

The objectives of this study were;
1. To differentiate patients with prostate cancer from those with BPH or ‘no cancer’.
2. To determine the difference in PCMP levels in the two groups namely,
a. Men with localized PCa
b. Men with biopsy proven BPH and no evidence of PCa.

3.3

Materials and Methods

After obtaining the necessary ethical approval was obtained from Western University
(Appendix 1), we analysed 405 plasma samples. 249 PCa plasma samples were obtained
from Ontario Institute of Cancer Research (OICR) and 147 samples of patients with
prostate biopsy proven BPH were obtained from Princess Margaret Hospital GU Tissue
Bank (PMH). We also recruited 9 patients with BPH at London Heath Sciences (LHSC),
these patients had a TRUS biopsy to rule out PCa and also underwent transurethral
resection with histologically confirmed BPH.
Collection of Samples
Sample from Tumor Bank: The samples were obtained from the tumour banks in aliquots
of 3-5 ml of frozen plasma. Services of an appropriate transportation company were
engaged to ensure that the samples were transported frozen at -80 degrees Celsius. These
samples were obtained from patients prior to definitive treatment for PCa. Each patient
donated around 10-15ml of blood which was obtained in a 4.5 mL EDTA vacutainer
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(Purple top tubes). The vacutainer was centrifuged at 2000 RCF for 20 min. This resulted
in the blood separating into two distinct layers, a red layer (erythrocytes) and a yellow
upper layer (platelet poor plasma-PPP). Using a plastic disposable Pasteur pipet, the PPP
was transferred into tube for storage at -80 degree Celsius.
Samples from London Health Sciences: Nine samples were obtained from patients
undergoing transurethral resection of prostate (TURP). These patients were previously
worked up for lower urinary tract symptoms and presence of PCa was ruled out by
transrectal ultrasound guided biopsy. The final pathology report from the TURP
specimen was consistent with histological diagnosis of BPH. Prior to surgery 10-15 ml of
blood was drawn in a purple top tube and centrifuged at 2000 RCF for 20 min. This
resulted in the blood separating into two distinct layers, a red layer (erythrocytes) and a
yellow upper layer (platelet poor plasma-PPP). Using a plastic disposable Pasteur pipet,
the PPP was transferred into tube for storage at -80 degree Celsius.
Randomization and blinding
All the samples were thawed and aliquoted again. The samples were randomized and
numbered to blind the observer during analysis of samples. These randomized and
relabelled samples were stored at -80 degree Celsius until they were used during the
experiment. The master list was kept separately in the office of Dr. Hon Leong, PhD.
Preparation of samples
We prepared two mixtures of antibodies in two different tubes to be used in this
experiment. We labeled one tube as ‘positive antibody’ and the second as ‘isotype
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antibody’. Isotype antibodies were used as control for each sample as the florescenceconjugated antibodies known to bind with trace amounts of nonspecific proteins and
produce auto florescence. The use of isotype antibodies helped us in identifying this
background noise. The numbers of events in the isotype sample were then subtracted
from the counts observed in the sample, labeled as ‘positive antibody’. This methodology
helped in eliminating the effect of this non specific binding. The positive antibody tube
was used to prepare a mixture of antibodies namely PSMA-PE antibody (3/E7), Ghrelin
peptide, GRPR antibody. Similarly we prepared a mixture of isotype controls for using
mouse IgG-RPE antibody for PSMA, Ghrelin/LCE antibody for ghrelin and rabbit IgG
antibody for GRPR for the tube labeled as isotype antibody. The concentration of PSMAPE antibody (3/E7) used was 408.42 µg/ml, the concentration of Ghrelin peptide used
was 62.5mM and the concentration GRPR used was 0.5 µg/ml. The concentrations of
isotype antibodies were matched.
To simplify the process of conjugation of the antibodies we prepared two cocktails. The
tube labeled positive contained; 24µL of GRPR, 24 µL of 2° antibody, 12 µL each of
PSMA mAb and Ghrelin peptide. The total volume of this mixture was 72 µL. Similarly
we used 24 µL of rabbit IgG antibody for GRPR, 24 µL of 2° antibody and 12 µL each of
mouse IgG-RPE antibody for PSMA, Ghrelin/LCE antibody for Ghrelin. The total
volume of this mixture was also 72 µL. This volume was enough to conduct the
experiment on a batch of 10 samples at one time.
We transferred 20 µL of platelet poor plasma (PPP) from a sample to two sterile 1.5 mL
eppendorf tubes. The tubes were labeled as tube ‘+ve’ and ‘–ve’ and given a numbers xxx
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according to previous randomization.

We added 6 µL from tube labeled ‘positive

antibody’ to the tube labeled ‘+ve’ xxx and 6 µL from tube labeled ‘isotype antibody’ to
the tube labeled ‘-ve’xxx.
Both the tubes were mixed well and immediately incubate in the dark for 30 min. After
incubation we added 600uL of sheath fluid (1X PBS, pH 7.4) using 1000 uL pipetman to
each tube and vortexed.
Analysis of samples on Flow cytometer
The samples were analysed on A−50 Micro nanoscale flow cytometer (Apogee Flow
Systems Inc.) to enumerate events. The optimization was performed using samples from
healthy volunteers and patients with high volume/grade PCa. We used varying
concentrations for antibodies during the optimization stage and chose the concentration
which revealed the maximum discrimination in the two selected populations. We then
selected our gates for calculation of the events. Each event seen on the histogram is a
reflection of a single MP captured as a result of binding to a specific antibody. The
location of each event on the histogram is a reflection of the characteristic of its
florescence and size.

Apogee A-50 nanoscale flow cytometer has the capacity to

discriminate events generated by submicron structures. We selected specific gates to
capture a selected population of MP. These gates were created by drawing boundaries
around the population of interest, which was identified during the optimization as most
discriminatory between the two groups. Figure 10 illustrates the settings for the
histograms.
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We then analyzed our study samples and used the same settings (identified during
optimization) throughout the study. The numbers of events per microliter were recorded
for each sample. The isotype controls were used to calculate the background activity of
each sample. We subtracted the number of events in the isotype from the sample to
calculate the ‘compensated’ number of microparticles events for each specimen.

3.4

Statistical Analysis

We used SPSS version 21.0 for statistical analysis. One-way ANOVA test (Ordinary)
was used to compare the mean number of events in the two groups using. The confidence
interval was set at 95% and the p-value of < 0.05 was considered significant.
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Long Angle
Light Scatter (size)

Small Angle
Light Scatter (size)

Ghrelin-Cy5

PSMA-PE

Figure 10. Histogram from Apogee A-50 nanoscale flow cytometer obtained
from a patient plasma from group 1 representing patients with prostate cancer
The top panel (A) represents all microparticle events analyzed according to
size (long angle vs. small angle light scatter, Y vs. X axis respectively). The
bottom panel (B) represents those same events but analyzed for PSMA +
Ghrelin, dual positive MP, On Y axis is Ghrelin-Cy5 and on X axis is
PSMA-PE.
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3.5

Results

Four hundred and five randomized samples were analyzed. The patients were divided in
two groups. Group 1 representing 249 patients with prostate cancer and Group 2 included
156 patients with BPH.
In Group 1 (PCa), 65% patients were aged between 40-64 years (range 49-79 years). The
mean PSA was 13.88 + 62.22 ng/mL (range 1.5 ng/mL to 541 ng/mL) and the median
PSA was 7 ng/ml. The pathologic T stage of the tumors (Group 1) is shown in Table 4
and the distribution of Gleason Score is shown in Table 5. In Group 2 (BPH), the mean
age of patients was 64.5 + 6.19 years (range 49-79 years). All patients in Group 2 had
biopsy proven BPH, the median size of the prostate gland was 67.5 grams calculated on
trans-rectal ultrasound. The mean PSA was 10.07 + 5.82ng/mL and the median PSA was
8.7 ng/ml.
Group 1 contained 249 patients diagnosed with PCa. The mean number of PSMA
positive events in this group was 160412 + 11480 events/µL. The mean number of PSMA
and Ghrelin (dual positive events), PSMA and GRPR (dual positive events) and
PSMA/Ghrelin/GRPR (triple positive events) is shown in Table 6.
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pT Stage (n=164)

Number of Patients (%)

pT2a

38 (23.1)

pT2b

16 (9.7)

pT2c

39 (23.7)

pT3a

46 (28)

pT3b

23 (14)

pTx

2 (1.2)

Table 4. Distribution of Pathologic T stage in Group 1

66

Gleason Score (n=185)

Number of Patients (%)

6

53 (28.6)

7

114 (61.6)

8

5 (1.0)

9

13 (7.0)

Table 5. Distribution of Gleason Score in Group 1
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Group 2 was comprised of 156 samples from patients with BPH. The mean number of
PSMA positive events in this group was 186119 + 20231 events/mL. The mean number
of PSMA and Ghrelin, PSMA and GRPR (dual positive events) and PSMA and Ghrelin
and GRPR (triple positive events) is shown in Table 7. A comparison of the mean
number of MP events for each type of MP in the two groups is shown in Figure 12.
We compared the number of events in the two groups using the one-way ANOVA
(Ordinary) test to compare the means. The confidence interval was set at 95% and a pvalue of < 0.05 was considered significant. Table 8 shows the comparison of the number
of microparticle

events expressing various biomarkers in the two groups. This

comparison is also shown in Figure 13.
We did not find any significant differences in mean number of PSMA positive
microparticle events,

PSMA+GRPR or PSMA+Ghrelin dual positive microparticle

events, or PSMA+Ghrelin+GRPR triple positive microparticle events.
We also looked at the distribution of the number of MP subtypes in different subgroups
of PSA and Gleason Score. Figure 16 and Figure 17 show the number of MP expressing
various biomarkers in the three tiers of PSA levels i.e. < 4ng/ml, 4-10 ng/ml and
>10ng/ml in Group 1 and Group 2. Figure 18 shows comparison of number of MP events
expressing various biomarkers in the two groups stratified by levels of PSA.
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PSMA

PSMA+GRPR

PSMA+Ghrelin

+ve
events/µL

Dual +ve
events/µL

Dual +ve
events/µL

PSMA+GRPR+
Ghrelin
Triple +ve
events/µL

Mean

160412

55177

56658

7909

Median

99585

21144

38594

3163

SEM

11480

5413

5376

696

Table 6. Microparticle Events Expressing Various Biomarkers (Prostate Specific
Membrane Antigen/PSMA, Gastrin-Releasing Peptide Receptor/GRPR, Ghrelin peptide
ligand/Ghrelin) in Plasmas from Patients with Prostate Cancer (PCa, Group 1). N=249.
The Mean, Median and Standard Error were calculated using SPSS version 21.0.
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PSMA

PSMA+GRPR

PSMA+Ghrelin

+ve
events/µL

Dual +ve
events/µL

Dual +ve
events/µL

PSMA+GRPR+
Ghrelin
Triple +ve
events/µL

Mean

186119

45885

67284

8946

Median

86155

17407

49973

2483

SEM

20231

5549

5795

1142

Table 7. Microparticles Events Expressing Various Biomarkers (Prostate Specific
Membrane Antigen/PSMA, Gastrin-Releasing Peptide Receptor/GRPR, Ghrelin peptide
ligand/Ghrelin) in Plasmas from Patients with Benign Prostatic Hyperplasia (BPH, Group
2). N=156. The Mean, Median and Standard Error were calculated using SPSS version
21.0.
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Number of MP Events/µL
Figure 11. Mean Concentration of MPs Expressing Various Biomarkers; PSMA, PSMA
+ GRPR, PSMA + Ghrelin and PSMA + GRPR + Ghrelin in Prostate Cancer Patient
Plasmas (Blue, N=249) and BPH Patient Plasmas (Red, N=156). One-way ANOVA
(Ordinary) test was used to compare the means of the two groups.
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Mean # events/µL
PSMA +ve MPs
PSMA+GRPR
Dual +ve MPs
PSMA+Ghrelin
Dual +ve MPs
PSMA+GRPR+Ghrelin
Triple +ve MPs

Group 1
(n=249)
160412 + 11480
55177 + 5413

Group 2
(n=156)
186119 + 20231
45885 + 5549

p-value

56658+ 5376

67284 + 5795

0.196

7990 + 696

8946 + 1142

0.411

0.235
0.254

Table 8. Concentration of MPs Expressing Various Biomarkers in Prostate Cancer Patient
Plasmas (Group 1) and BPH Patient Plasmas (Group 2). One-way ANOVA (Ordinary)
test was used for comparison using SPSS version 21.0.
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Number of MP Events/µL

Figure 12. Mean Concentration of MPs Expressing Various Combinations of Biomarkers
in Prostate Cancer Patient Plasmas (N=72) Stratified into Three PSA Groups (PSA < 4
ng/mL, 4-10 ng/mL and >10 ng/mL).
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Number of MP Events/µL

Figure 13. Mean Concentration of MPs Expressing Various Combinations of Biomarkers
in BPH Patient Plasmas (N=143) stratified in Three PSA Groups (PSA < 4 ng/mL, 4-10
ng/mL and >10 ng/mL).
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We compared PSMA positive microparticle events, PSMA+GRPR or PSMA+Ghrelin
dual

positive

microparticle

events,

and

PSMA+Ghrelin+GRPR

triple

positive

microparticle events to determine if this test was able to differentiate between the patients
with cancer and BPH in any subgroup, stratified on the basis of PSA cutoff, but we did
not find any statistically significant difference. Table 9, 10 and 11 shows the comparison
in different in the different PSA tiers with BPH group.
We also compared PSMA positive, PSMA+GRPR or PSMA+Ghrelin, dual positive, and
PSMA+Ghrelin+GRPR triple positive microparticle events in patients with different
Gleason score and BPH. We divided the patients with PCa in three groups comprising of
patient plasma from Gleason score < 6, 7 and > 8. The main limitation of this comparison
was the small number of patients in the subgroups. We found significantly higher number
of PSMA+ Ghrelin dual positive in BPH group in comparison with all the subgroups of
patients with PCa. This Gleason score wise comparison using various biomarkers with
patient plasmas from BPH is shown in Figure 15. We also found a statistically
significant difference in PSMA only positive MP events in the Gleason score 7 and >8
compared with BPH but the association was opposite in these groups. PSMA only
positive MP were significantly higher in BPH compared to Gleason score 7 (p=0.003)
and

significantly

lower

in

BPH

compared
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to

Gleason

score

>8

(p=0.01).

Events/µL
PSMA
+ve
PSMA+GRPR
Dual +ve
PSMA+Ghrelin
Dual +ve
PSMA+GRPR+
Ghrelin
Triple +ve

Group 1
(n=9)
196346 + 38709

Group 2
(n=8)
331700 + 113016

91438 + 29595

26933 + 7931

31414 + 6241

88785 + 26352

13226 + 3707

4754 + 2229

p-value and
Confidence Interval
0.821
(-157910 to 198622)
0.057
(-252 to 98562)
0.998
(-53758 to 53660)
0.233
(-3909 to 15949)

Table 9. Comparison of Concentration of MPs Expressing Various Biomarkers in
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for
Patients with PSA < 4ng/mL. One-way ANOVA (Ordinary) test was used for
comparison.
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Events/µL
PSMA
+ve
PSMA+GRPR
Dual +ve
PSMA+Ghrelin
Dual +ve
PSMA+GRPR+
Ghrelin
Triple +ve

Group 1
(n=49)
104401 + 33473

Group 2
(n=79)
165908 + 21516

33435 + 6349

46502 + 7102

-7339 + 31171

66945 + 5675

5224 + 1163

9227+ 1422

p-value and
Confidence Interval
0.832
(-152654 to 9476)
0.1033
(-37699 to 3503)
0.1037
(-85615 to 8011)
0.3516
(-6168 to 2204)

Table 10. Comparison of Concentration of MPs Expressing Various Biomarkers in
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for
Patients with between PSA 4 to 10 ng/mL. One-way ANOVA (Ordinary) test was used
for comparison.
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Events/µL
PSMA
+ve
PSMA+GRPR
Dual +ve
PSMA+Ghrelin
Dual +ve
PSMA+GRPR+
Ghrelin
Triple +ve

Group 1
(n=22)
141613 + 34053

Group 2
(n=56)
218981 + 42493

26810 + 11593

54918 + 11170

32318 + 6917

74733 + 12894

3724 + 1053

10646 + 2338

p-value and
Confidence Interval
0.537
(-144092 to 75338)
0.3085
( -45366 to 14422)
0.9589
(-31844 to 33554)
0.2494
(-9429 to 2465)

Table 11. Comparison of Concentration of MPs Expressing Various Biomarkers in
Prostate Cancer Patient Plasmas (Group 1) and BPH Patient Plasmas (Group 2) for
Patients with between PSA >10 ng/mL. One-way ANOVA (Ordinary) test was used for
comparison.
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Number of MP Events/µL

PSA > 10

Number of MP Events/µL

Number of MP Events/µL

PSA < 4

PSA = 4-10

RED – BPH
BLUE – PCa

Figure 14.Comparison of Mean Concentration of MPs Expressing Various
Combinations of Biomarkers in Prostate Cancer Patient Plasmas (Blue, N=74) and
BPH Patient Plasmas (Red, N=143) stratified in Three PSA Groups (PSA < 4 ng/mL,
4-10 ng/mL and >10 ng/mL). One-way ANOVA (Ordinary) test was used to compare
the means of the two groups.
79

Number of MP Events/µL

leason Score 6

Figure 15. Comparison of Various Combinations of Biomarkers in Prostate
Cancer Patient Plasmas with Gleason Score 6, 7 and > 8 and BPH Patient
Plasmas. One-way ANOVA (Ordinary) test was used to compare the means
of the two groups. * denotes statistical significance.
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3.6

Discussion

The concerted efforts to develop a biomarker for screening of prostate cancer (PCa) have
been significantly accelerated after the publication of recent reports that have highlighted
the potential harms of prostate specific antigen (PSA) based screening (Andriole et al.
2009). In this study we investigated a blood test based on enumeration of microparticle
(MP) as a biomarker to identify PCa. MPs are defined as plasma membrane derived
structures of a diameter of less than 1000nm. They are released from the cell upon
activation, death, apoptosis or malignant transformation and inherit surface receptors
from their cell of origin (Rak, 2013).

Using monoclonal antibodies (mAb) specific for

these antigens it may be possible to identify them. Surgical pathologists have used this
technique to interpret specimens from metastatic sites with unknown primary lesion.
mAb against cell specific receptors are used identify the primary site of origin of these
metastatic lesions. Modified monoclonal antibodies have also been used as imaging
agents and tagged with therapeutic arsenal to deliver targeted therapy (Deckert et al.
2009).
In this study we investigated four biomarkers to differentiate patients with PCa from
benign prostatic hypertrophy (BPH). We selected mAb specific for prostate specific
membrane antigen (PSMA) and gastrin releasing peptide receptor (GRPR). We also
selected ghrelin peptide, a ligand for growth hormone secretagogue receptor (GHSR).
The four biomarkers were PSMA alone and a combination of PSMA with GRPR and or
Ghrelin.
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Sokoloff et al. have demonstrated that PSMA is expressed more than 100 fold higher in
prostate cancer cells in comparison to normal prostate cells (Sokoloff et al. 2000). PSMA
based imaging (ProstaScint scan, Cytogen, Philadelphia, PA) for metastatic evaluation of
PCa is US-FDA approved, however it has not been shown to be very effective (Rosenthal
et al. 2001). The limited success of ProstaScint scan is mainly attributed to the long
scanning time. The PSMA antibody used in this imaging modality was required to be
injected several days before the planned imaging, thus making it less attractive for
practical clinical use (Foss et al. 2012). A recent review analyzing published literature
investigating PSMA in the last 20 years reveals robust research and an optimistic future
for PSMA based treatment for castrate resistant PCa (Ritasu et al. 2013). In our study
PSMA positive MP events were non-significantly elevated in the BPH group (p=0.235).
The subgroup analysis according to the PSA tiers of <4 ng/ml, 4-10 ng/ml and >10 ng/ml
also did not reveal any significant difference in the PSMA positive MP counts among the
two groups. However, PSMA positive MP were significantly higher in BPH compared to
Gleason score 7 (p=0.003) and significantly lower in BPH compared to Gleason score >8
(p=0.01). As the number of patients in Gleason >8 category was small (n=18) we are
unable to draw any meaningful conclusion.
PSMA + GRPR, dual positive MP events were also investigated as a potential biomarker.
Beer et al. in his study had demonstrated that two third of primary prostate cancer stain
positively with GRPR (Beer et al. 2012). In another study looking at co-expression of
PSMA and GRPR found the all cases of metastatic PCa stained positively for PSMA and
87% also co-stained with GRPR (Ananias et al. 2009). In our study we found statistically
insignificant difference in PSMA+GRPR, dual positive MP in the PCa group (p=0.254).
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In the sub group analysis we found this difference to approach statistical significance (p=
0.057) in the sub group of patient plasma with PSA of < 4ng/ml. This finding needs
further investigation as the number of patients both the groups was very small ( n=8 vs.
n=9).
In our pilot study we found PSMA + Ghrelin, positive dual positive MP events to
discriminate patients with PCa (Siddiqui et al. 2013). On contrary to our expectation in
this study we found this biomarker to be elevated in patients with BPH. Overall the
difference in PSMA + Ghrelin, dual positive MP events was not statistically significant
(p=0.998). In subgroup analysis PSMA + Ghrelin, dual positive MP events were
significantly higher in BPH group compared to all categories of Gleason score. This find
may have been due to the fact that patients in BPH group had a higher median PSA
compared to PCa group (7ng/ml vs. 8.7ng/ml). But when we controlled for PSA, the
subgroup analysis did not show any significant difference. The other theoretical
possibility may be that patients in the BPH group harbored an occult focus of PCa.
PSMA + GRPR + Ghrelin, triple positive MP was evaluated as the fourth biomarker in
this study. We found this to be also non discriminatory (7990 + 696 vs. 8946 + 1142,
p=0.411). Thus all four biomarkers studied in were not able to discriminate patients with
PCa from BPH.
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3.7

Conclusions

Prostate cancer MP can be enumerated by nanoscale flow cytometer proving the utility of
Apogee A-50 flow cytometer to detect MP. This enhances our capacity of analyze MP in
a high throughput and multi-parametric manner.
Although, all four biomarker were not able to discriminate patients with PCa from patient
with BPH but in patients with PSA <4ng/ml, PSMA+GRPR dual positive MP showed a
trend toward statistical significance in discrimination between the two groups. Further
exploration of this biomarker with larger numbers may help in identifying a biomarker
which can help discriminate patients with PSA in this range. The subgroup analysis
comparing Gleason score and BPH showed that PSMA + Ghrelin, dual positive MP was
higher in the BPH.
A blood test based on enumeration of MP may hold the promise as it has the potential to
measure prostate cancer fragments continuously released from cancer cells. When
perfected this test may be used as a fluid biopsy to continually sample the tumor.
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4

Chapter 4

4.1 General Discussion
Synchronous improvement in quality of care, dissemination of refined surgical technique,
improvement in the radiation technology along with the early stage of PCa at presentation
has contributed to better outcomes of prostate cancer. However, we now see a plateau in
the mortality curves (Otis et al. 2012). The plateau reflects that we are not diagnosing all
patients and that treatment is still not perfect. We know that PSA is not a true tumor
marker for prostate cancer and this surrogate marker may be raised in a number of nonmalignant conditions. Transrectal ultrasound (TRUS) guided prostate biopsy is the corner
stone of management and is the most common modality to obtain a histological diagnosis
which is a mandatory investigation for definitive diagnosis. A standard 8-12 core biopsy
is reported to have a positive yield of around 50% (Lawrentschuk et al. 2009). Therefore,
for the majority of men a biopsy recommended due to an elevated PSA fail to reveal the
diagnosis of PCa and often they are undergo more than one biopsy procedure (Shinohara
et al. 2014). This potentially exposes them to the complications of the procedure and is a
cause of persistent anxiety. Ideally, we need a cost effective test that can confidently
diagnose cancer and this test should be able to predict its clinical course. This test should
preferably also avoid the need for biopsy or recommend biopsy for a very select
population. To meet the challenge of a screening test superior to PSA, we attempted to
explore a prostate microparticle-based “fluid biopsy” which could continually sample the
prostate gland and its primary tumor to gain insight regarding the biology of these tissues.
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MP released into blood, urine, and body fluids offers a novel opportunity to sample the
biological information from the mutant cancer cell along with the normal stromal cells.
This

MP

based

sampling

has

the

potential to

be

superior

to

conventional

histopathological assessment as this fluid biopsy may be able to capture information not
limited by the anatomical boundaries of the pathology slide and provide a holistic view
regardless of the regional differences observed in a tumor effected prostate gland
(Heppner et al. 1984).
Microparticles by our definition exhibit a diameter smaller than one micron and are
manifest as fragments released from the cancer cell's surface. Our laboratory has
validated the presence of MP by atomic force microscopy and have also analyzed them
using flow cytometry (Leong et al. 2011). These MP retain the surface receptors present
on the cells of origin. The significance of this in oncogenesis is still not determined but
this property makes them potentially useful as disease biomarkers. We used the Apogee®
A-50 nanoscale flow cytometer which has three lasers and is capable of recording dual
and triple florescence positive events.

Our laboratory was the first one to acquire this

technology in North America and is still among the few in Canada to have the capacity to
use the A-50 micro nanoscale flow cytometer.
We selected PSMA, GRPR and GHS receptor as these are surface receptors documented
to be present on prostate cancer cells. It has been demonstrated that PSMA is expressed
more than 100 fold higher in prostate cancer cells in comparison to normal prostate cells
(Sokoloff et al. 2000). This led to development of PSMA antibodies which selectively
target prostate cancer cells both at the primary site and at the site of metastasis. In a phase
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1 trial, radio therapeutic agent Lutetium-177 was tagged to the PSMA antibody (J591) for
treatment of metastatic lesions of castrate resistant prostate cancer with acceptable
toxicity (Bunder et al. 2005). In a phase 2 trial, 60% PSA response was observed in
patients treated with PSMA based antibody (Tagawa et al. 2008). A query for “PSMA”
and “prostate cancer” reveals 14 current clinical trials (http://www.clinicaltrials.gov)
exploring the role of PSMA in prostate cancer. The initial interest in PSMA antibody was
for its potential role in imaging for prostate cancer however, the downside to antibodybased imaging is the long time required for the antibody to clear from non-target tissues.
This means that the antibody should be injected several days before the planned imaging,
making it less attractive for practical clinical use (Foss et al. 2012).
We explored the possibility of PSMA expression on MPs. In the pilot study we found that
PSMA positive MPs can be enumerated using Apogee® A-50 nanoscale flow cytometer.
In our pilot study we also found a stronger expression of PSMA positive MP in the
patients with PCa in comparison with healthy volunteers and patients with BPH. In this
study, the majority of samples in the control group were obtained from healthy volunteers
and only 9 patients with BPH were included. The healthy volunteers in this study were
aged younger than 35 years and did not have any history of cancer.

All groups did

express PSMA positive events and this showed that PSMA positivity is not exclusive for
prostate cancer. In our study, we were able to enumerate PSMA positive MPs but found
statistically insignificant differences in MPs enumerated in the two groups. In contrary to
our expectation we found a trend towards higher number of events in patients with BPH
compared to PCa. We postulated that looking for co-expression of more than one
biomarker would increase the specificity of prostate cancer specific biomarkers. We used
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PSMA as our prostate-specific biomarker, and GRPR antibody and Ghrelin peptide
(ligand) as our cancer-specific biomarkers.

Previous work in our laboratory had earlier

confirmed that fluorescein labeled Ghrelin is over expressed in PCa compared to normal
prostate (Lu et al. 2012). This study looked at PC3 and LNCaP cell lines along with
specimens obtained from radical prostatectomy and concluded that this Ghrelin analog
could be used as an imaging probe for PCa. In our pilot study with PSMA and Ghrelin
dual positive markers we found this test to successfully discriminate PCa from the control
but in our main study, we found that PSMA+Ghrelin dual positive MP events were
higher in the BPH group compared to the cancer group (67284 + 5795 vs. 56658 + 5376,
p=0.196).
This was an unexpected finding as based on our pilot study we anticipated this to be the
contrary. The possible reasons for this difference in expected vs. observed maybe due to
the fact that in our pilot study we compared patients with prostate cancer with mainly
healthy controls and not BPH which is a benign tumor and may actually have over
expression of PSMA. Due to the small number of patients with BPH in the pilot study
this observation could have been masked. The patients in the BPH group also had a
higher median PSA as compared to the cancer group, 8.7ng/ml vs.7 ng/ml. Although all
the men in the BPH group had a TRUS biopsy to rule out prostate cancer, they were to
begin with, at a high risk of having cancer which had initiated the biopsy. The risk of
having a high volume PCa was ruled out with the prostate biopsy but we also understand
that TRUS biopsy has its limitations and it is even possible that some of the patients in
the BPH group actually had a focus of cancer which was missed at the biopsy. These are
the inherent limitations of our control population. We designed this study to compare the
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utility of these markers for distinguishing patients with prostate cancer from those with
no cancer. This clinical equipoise is present in men who are recommended a biopsy
hence we chose this control. This selection was made after we had documented in our
pilot study that the MP are more abundant in the prostate cancer patients compared with
healthy controls. We now desired to reproduce the results in a large number of samples
from the patients who do not have prostate cancer and were able to have access to
specimens from a bio bank which stored such samples. We presumed that this age and
gender matched population would be an ideal control for the overall objective of the
study. In our study we also noticed a large standard deviation in the number of events.
This could mean that either the test fails to identify the MP or our group of patients in the
control group is very heterogeneous mixture.
We also used an additional third marker, GRPR for this experiment and enumerated
PSMA and GRPR positive MP. We also used a combination of all three makers to
identify MP which express all three surface antigens. This strategy was designed to
further enhance the specificity of the test for enumeration of PCMP. Enhanced GRPR
expression has previously been reported on PCa cells in vitro (Bologna et al. 1989).
GRPR expression was further confirmed by studies which demonstrated growth of
prostate cancer cells stimulated by the gastrin releasing peptide and inhibited by
antagonists of GRP (Milovanovic et al. 1992). Another study found co-expression of
GRPR and PSMA in both nodal and bony metastatic lesions of PCa (Ananias et al.
2009). Similar expression was also demonstrated in primary prostate carcinomas (Beer et
al. 2012).
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In our study we enumerated PSMA and GRPR, dual positive MP and PSMA, Ghrelin and
GRPR, triple positive MP and did not find any significant difference in the number of
PSMA and GRPR dual positive (55177 + 5413 vs.45885 + 5549, p=0.254) and PSMA
and GRPR and Ghrelin triple positive markers (7990 + 696 vs. 8946 + 1142, p=0.411) in
the two groups. Thus this combination was also not able to discriminate patients with
PCa from BPH.
When we controlled for PSA and divided our patients in three groups i.e. PSA <4 ng/mL,
4 to 10 ng/mL and >10 ng/mL and compared the number of MP events in the two groups,
we did not find any statistically significant difference. However, when we compared the
number of MP events for various biomarkers expressed in three different histological
grades (Gleason scores 6, 7 and > 8) with patient plasma from Group 2 (BPH), a
statistically significant difference in MP expressing PSMA and Ghrelin dual positive
events was seen in Gleason score 6 and 7 (p=0.001). Similarly a statistically significant
difference was also observed in the number of MP expressing PSMA only, in the Gleason
score >8 compared with BPH (p=0.01).

The higher number of PSMA and Ghrelin, dual

positive events in the BPH group was in contrary to our expectation. We anticipated a
stronger expression of this biomarker in patient plasma with PCa. However the small
sample size in this subgroup and the imbalanced groups used for comparison may have
accounted for this statistical significance.

nclusion
Our blood test based on PSMA, Ghrelin peptide ligand and GRPR has not been able to
successfully differentiate patients with prostate cancer from those with BPH. However,
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we have been able to enumerate microparticle expressing single, dual or triple positive
events. This proves the utility of flow cytometer to detect MP in a high throughput and
multiparametric manner. A blood test based on enumeration of MP holds the promise as
it has the potential to measure prostate cancer fragments continuously released from
cancer cells. When perfected this test may be used as a fluid biopsy to continually sample
the tumor.

4.2

Future Directions

Our laboratory is currently investigating other biomarkers like prostate stem cell antigen
(PSCA), TMPRSS2, AMACR etc. We plan to analyze PSMA + GRPR dual positive MP
for patients with BPH and PCa having a PSA < 4 ng/ml. In this regard we have identified
a source of patient plasmas with BPH and PSA of < 4ng/ml. Increasing the power of
study to assess this biomarker may reveal interesting results. We are designing a study to
explore PSMA + Ghrelin, dual positive MP as a biomarker for BPH. In collaboration
with London bio-bank we are recruiting patients ahead of TRUS biopsy. These patients
will also have serial blood samples. The longer follow-up will significantly strengthen the
control group for future experiments.
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